Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab

Activating RAS mutations occur in more than a half of colorectal cancers (CRCs). RAS-mutated CRCs are notoriously difficult to treat given that they are characterized by the aggressive disease course and the lack of appropriate targeted therapies. Recent preclinical studies demonstrated that RAS-mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Orlov, Sergey V., Urtenova, Magaripa A., Sviridenko, Maria A., Nesterov, Denis V., Sokolova, Tatiana N., Imyanitov, Evgeny N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506371/
https://www.ncbi.nlm.nih.gov/pubmed/32999660
http://dx.doi.org/10.1159/000509241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506371/
https://www.ncbi.nlm.nih.gov/pubmed/32999660
http://dx.doi.org/10.1159/000509241

Ejemplares similares